⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413240 | 0.76 | — | — | |
| SCHEMBL456126 | 0.76 | — | — | |
| SCHEMBL15541066 | 0.76 | — | — | |
| SCHEMBL3071411 | 0.76 | — | — | |
| SCHEMBL1041994 | 0.76 | — | — | |
| SCHEMBL30626044 | 0.75 | HDAC8 (0.40) | — | |
| SCHEMBL27733 | 0.75 | HDAC8 (0.40) | — | |
| SCHEMBL24435938 | 0.73 | GRM5 (0.51) | — | |
| SCHEMBL29598220 | 0.73 | GRM5 (0.51) | — | |
| SCHEMBL15516427 | 0.73 | GRM5 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114361590-B | Electrolyte additive for lithium ion battery, electrolyte and lithium ion battery | 松山湖材料实验室 | 2023-07-25 | — | — | CN | claimed |
| CN-114361590-A | Lithium ion battery electrolyte additive, electrolyte and lithium ion battery | 松山湖材料实验室 | 2022-04-15 | — | — | CN | claimed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| EP-4631940-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025107579-A1 | COMPOUND TARGETING UBIQUITIN KRAS PROTEIN DEGRADATION AGENT, AND USE THEREOF | 贝达药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025039676-A1 | PAN-KRAS PROTEIN TARGETED DEGRADER COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| WO-2024146617-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | 甘李药业股份有限公司 | 2024-07-11 | — | — | WO | disclosed |
| WO-2024120424-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | 贝达药业股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-20240059691-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | US | disclosed |
| EP-4255900-A2 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-10-11 | — | — | EP | disclosed |
| CN-101111499-B | Substituted ethynyl gold-nitrogen-containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES | 2012-05-23 | — | — | CN | disclosed |
| US-8137821-B2 | Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | UBE INDUSTRIES, LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| CN-101111499-A | Substituted ethynyl gold-nitrogenated heterocyclic carbene complex and organic electroluminescent device using same | UBE INDUSTRIES (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| CN-1882586-A | 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |